Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2016

View Archived Issues

Shanghai Institute Materia Medica develops tyrosine kinase inhibitors

ExpreS2ion and Abivax enter collaboration on Ebola prophylaxis and treatment program

Medicenna Biopharma begins phase II study of MDNA-55

European Commission grants conditional approval to Ocaliva

KemPharm reports positive results from phase I proof-of-concept study of d-MPH prodrug

ALS symptoms deteriorate after stopping ibudilast treatment in clinical trial

AN-13762 described as representing a new class of antimalarial

Novel therapeutic targets described at the Society for Neuroscience Annual Meeting

Concert Pharmaceuticals completes phase I study of JAK inhibitor for alopecia areata

TPC-064: a novel mutant-selective EGFR inhibitor

vTv Therapeutics reports topline data from phase II trial of TTP-273 in type 2 diabetes

Kiadis obtains U.K. approvals for phase I/II trial of ATIR-201 for thalassemia

FDA gives orphan drug designation to nintedanib in mesothelioma

Encouraging results reported from tolerability proof-of-concept study of KarXT

Epigenetic compound CTI-309 shows promise as Alzheimer's disease candidate

TSRI, Icahn School of Medicine and UPenn patent nAChR modulators

Bicycle Therapeutics collaborates with Cancer Research UK to study BT-1718

Harvard and Evotec divulge novel bacterial glycosyl transferase inhibitors

Merck & Co. discovers soluble guanylate cyclase activators

FDA approves Eucrisa for atopic dermatitis

Principia Biopharma patents new FGFR inhibitors

Chong Kun Dang Holdings divulges new histone deacetylase inhibitors

Hologic to divest blood screening business to Grifols

argenx initiates phase I/II study of ARGX-110 with azacitidine in newly diagnosed AML

Third Rock Ventures launches Goldfinch Bio with a focus on therapies for kidney disease

Biogen files for Japanese approval of nusinersen for SMA

Lonza set to acquire Capsugel

CM-4620 receives EMA orphan designation for acute pancreatitis

Gamunex-C granted FDA orphan status for myasthenia gravis

Polatuzumab vedotin given U.S. orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...